RU95101430A - Производные 1-бифенилметилимидазола, их получение, фармацевтическая композиция, способ лечения или профилактики гипертонии - Google Patents

Производные 1-бифенилметилимидазола, их получение, фармацевтическая композиция, способ лечения или профилактики гипертонии

Info

Publication number
RU95101430A
RU95101430A RU95101430/04A RU95101430A RU95101430A RU 95101430 A RU95101430 A RU 95101430A RU 95101430/04 A RU95101430/04 A RU 95101430/04A RU 95101430 A RU95101430 A RU 95101430A RU 95101430 A RU95101430 A RU 95101430A
Authority
RU
Russia
Prior art keywords
group
alkyl
rmeans
compounds
hydrogen
Prior art date
Application number
RU95101430/04A
Other languages
English (en)
Other versions
RU2128173C1 (ru
Inventor
Янагисава Хироаки
Jp]
Симодзи Ясуо
Фудзимото Коити
Каназаки Такуро
Амемийа Йосийа
Койке Хироюки
Сада Тосио
Original Assignee
Санкио Компани Лимитед (JP)
Санкио Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27549327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU95101430(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санкио Компани Лимитед (JP), Санкио Компани Лимитед filed Critical Санкио Компани Лимитед (JP)
Publication of RU95101430A publication Critical patent/RU95101430A/ru
Application granted granted Critical
Publication of RU2128173C1 publication Critical patent/RU2128173C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Dental Preparations (AREA)
  • Phenolic Resins Or Amino Resins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Предлагаемое изобретение относится к соединениям формулы 1, приведенной в описании. Указанные соединения и их фармацевтически приемлемые соли и - сложные эфиры обладают гипотенсивной активностью и могут быть использованы для лечения и профилактики гипертензии. Соединения настоящего изобретения могут быть получены, inter alia, посредством реакции бифенилметилового соединения с имидазоловым соединением.

Claims (1)

  1. Предлагаемое изобретение относится к соединениям формулы 1, приведенной в описании. Указанные соединения и их фармацевтически приемлемые соли и - сложные эфиры обладают гипотенсивной активностью и могут быть использованы для лечения и профилактики гипертензии. Соединения настоящего изобретения могут быть получены, inter alia, посредством реакции бифенилметилового соединения с имидазоловым соединением.
RU95101430A 1991-02-21 1992-02-21 Производные 1-бифенилметилимидазола, способ их получения и фармацевтическая композиция для лечения и профилактики гипертензии RU2128173C1 (ru)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
JP2709891 1991-02-21
JP3-27098 1991-02-21
JP3-96588 1991-04-26
JP9658891 1991-04-26
JP13488991 1991-06-06
JP3-134889 1991-06-06
JP3-167138 1991-07-08
JP16713891 1991-07-08
JP17397291 1991-07-15
JP3-173972 1991-07-15
JP18484191 1991-07-24
JP3-184841 1991-07-24

Publications (2)

Publication Number Publication Date
RU95101430A true RU95101430A (ru) 1997-02-20
RU2128173C1 RU2128173C1 (ru) 1999-03-27

Family

ID=27549327

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95101430A RU2128173C1 (ru) 1991-02-21 1992-02-21 Производные 1-бифенилметилимидазола, способ их получения и фармацевтическая композиция для лечения и профилактики гипертензии

Country Status (23)

Country Link
EP (2) EP0545912B1 (ru)
JP (1) JPH07121918B2 (ru)
KR (1) KR0128289B1 (ru)
CN (3) CN1045770C (ru)
AT (2) ATE200777T1 (ru)
CA (2) CA2061607C (ru)
CZ (1) CZ289194B6 (ru)
DE (6) DE10299043I2 (ru)
DK (2) DK0545912T3 (ru)
ES (2) ES2156866T3 (ru)
FI (2) FI112942B3 (ru)
GR (2) GR3035906T3 (ru)
HK (2) HK1011361A1 (ru)
HU (3) HU223338B1 (ru)
IE (1) IE920540A1 (ru)
IL (3) IL114996A (ru)
IS (1) IS1756B (ru)
LU (4) LU91056I2 (ru)
NL (3) NL300133I2 (ru)
NO (6) NO304516B3 (ru)
NZ (1) NZ241681A (ru)
PT (2) PT503785E (ru)
RU (1) RU2128173C1 (ru)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
PT573218E (pt) * 1992-06-02 2001-06-29 Sankyo Co 4-carbonilimidazoles como antagonistas de angiotensina ii e sua utilizacao terapeutica
RU2109736C1 (ru) * 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
RU2123847C1 (ru) * 1994-03-16 1998-12-27 Санкио Компани Лимитед Лекарственное средство и способ лечения повышенного глазного давления и/или глаукомы
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AUPN786896A0 (en) 1996-02-02 1996-02-29 Telstra Corporation Limited A network fault system
RU2183128C2 (ru) 1996-07-15 2002-06-10 Санкио Компани Лимитед Фармацевтическая композиция
WO1998034922A1 (fr) * 1997-02-05 1998-08-13 Sankyo Company, Limited Agent destine a la prophylaxie ou la therapie des complications diabetiques
WO2000078727A1 (fr) * 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Methode de preparation de derives d'imidazole
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4521844B2 (ja) * 2000-04-18 2010-08-11 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
NZ525913A (en) * 2000-11-21 2004-05-28 Sankyo Co A pharmaceutical composition
NZ531346A (en) * 2001-08-28 2005-10-28 Sankyo Co Medicinal compositions containing angiotensin II receptor antagonist
KR101194453B1 (ko) 2003-01-31 2012-10-24 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
CN1197866C (zh) * 2003-03-21 2005-04-20 上海医药工业研究院 4，6－二氢呋喃并[3,4－d]咪唑－6－酮衍生物及其盐和制备方法
EP1614428A4 (en) * 2003-04-15 2010-01-06 Sankyo Co MEDICAMENT FOR THE PREVENTION OR TREATMENT OF ANGIOGENIC OCULAR DISEASES
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
US7692023B2 (en) 2004-02-11 2010-04-06 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US20080161321A1 (en) 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
US7528258B2 (en) * 2004-09-02 2009-05-05 Teva Pharmaceutical Industries Ltd Preparation of olmesartan medoxomil
EP1799199B1 (en) 2004-10-08 2012-03-28 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
WO2006046593A1 (ja) 2004-10-27 2006-05-04 Daiichi Sankyo Company, Limited ２以上の置換基を有するベンゼン化合物
JP2007525504A (ja) * 2004-12-30 2007-09-06 テバ ファーマシューティカル インダストリーズ リミティド ２．５よりも高いｐＨでオルメサルタンメドキソミルを調製するための方法
WO2006073519A1 (en) * 2005-01-03 2006-07-13 Teva Pharmaceutical Industries Ltd. Olmesartan medoxomil with reduced levels of impurities
DE602006010364D1 (de) * 2005-04-22 2009-12-24 Daiichi Sankyo Co Ltd Pharmazeutikum zur prävention oder behandlung von metabolischer knochenkrankheit
US7943779B2 (en) * 2005-07-29 2011-05-17 Krka Process for the preparation of olmesartan medoxomil
EP1816131A1 (en) * 2006-02-06 2007-08-08 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of olmesartan medoxomil
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
CZ299902B6 (cs) * 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
EP1801111B1 (en) * 2005-12-20 2014-07-16 LEK Pharmaceuticals d.d. Novel polymorph forms of olmesartan medoxomil
JP5047156B2 (ja) * 2006-02-27 2012-10-10 武田薬品工業株式会社 医薬パッケージ
ATE526963T1 (de) 2006-05-04 2011-10-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit olmesartan- medoxomil
WO2007148344A2 (en) * 2006-06-19 2007-12-27 Matrix Laboratories Limited Process for the preparation of olmesartan medoxomil
US8242151B2 (en) 2007-02-07 2012-08-14 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2141160A4 (en) * 2007-03-23 2011-06-29 Daiichi Sankyo Co Ltd GROUND CRYSTAL OLMESARTAN MEDOXOMIL
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101311168B (zh) * 2007-05-21 2010-12-08 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法
CN101311169B (zh) * 2007-05-21 2011-03-16 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0710680D0 (en) * 2007-06-05 2007-07-11 Generics Uk Ltd Novel crystalline form of olmesartan medoxmil
WO2009001661A1 (ja) * 2007-06-22 2008-12-31 Daiichi Sankyo Company, Limited アルツハイマー病の予防又は治療のための医薬
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
ES2540062T3 (es) 2008-06-09 2015-07-08 Daiichi Sankyo Company, Limited Procedimiento de producción de un compuesto de 1-bifenilmetilimidazol
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP5559689B2 (ja) 2008-08-06 2014-07-23 協和発酵キリン株式会社 ３環系化合物
WO2010054515A1 (zh) 2008-11-17 2010-05-20 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法
JP2009102340A (ja) * 2008-12-04 2009-05-14 Daiichi Sankyo Co Ltd イミダゾール誘導体の製造法（２）
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2010126014A1 (ja) 2009-04-28 2010-11-04 第一三共株式会社 新規溶媒和物結晶
TWI539948B (zh) 2009-04-28 2016-07-01 第一三共股份有限公司 奧美沙坦酯之製造方法
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
CN102050816A (zh) * 2009-10-28 2011-05-11 北京万全阳光医学技术有限公司 一种合成奥美沙坦酯的方法
HUP0900788A2 (en) 2009-12-16 2011-11-28 Sanofi Aventis Process for producing 4-bromomethyl-biphenyl derivatives
WO2011083112A2 (en) 2010-01-05 2011-07-14 Ratiopharm Gmbh Solid oral dosage form containing olmesartan medoxomil
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP5137996B2 (ja) * 2010-04-28 2013-02-06 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102060778B (zh) * 2010-12-24 2012-05-23 江苏江神药物化学有限公司 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法
CN102206208A (zh) * 2010-12-24 2011-10-05 上海现代制药股份有限公司 含低水平杂质的奥美沙坦酯的制备方法
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
TW201311678A (zh) 2011-08-03 2013-03-16 Kyowa Hakko Kirin Co Ltd 二苯并氧呯衍生物
BR112014014527A2 (pt) 2011-12-15 2017-06-13 Takeda Pharmaceuticals Usa Inc combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
CN103304550B (zh) * 2012-03-16 2016-01-27 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
US9624181B2 (en) 2012-08-31 2017-04-18 Api Corporation Method for producing biaryl compound
JP5881837B2 (ja) 2012-09-26 2016-03-09 株式会社エーピーアイ コーポレーション テトラゾール化合物の脱保護方法
JP6218084B2 (ja) 2012-10-04 2017-10-25 国立研究開発法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CN103012382B (zh) * 2012-12-05 2016-10-05 迪沙药业集团有限公司 一种奥美沙坦酯的制备方法
CN103044407A (zh) * 2012-12-20 2013-04-17 安徽悦康凯悦制药有限公司 奥美沙坦酯的制备方法
CN103965167A (zh) * 2013-01-29 2014-08-06 通化济达医药有限公司 咪唑羧酸衍生物
JP2014152127A (ja) * 2013-02-06 2014-08-25 Tokuyama Corp オルメサルタンメドキソミルの製造方法
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP3025711B1 (en) 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medicine for preventing or treating hypertension
CN103880825B (zh) * 2014-03-14 2019-03-05 浙江华海药业股份有限公司 一种高纯的三苯甲基奥美沙坦酯的制备工艺
CN104356069B (zh) * 2014-11-18 2016-09-14 黄冈鲁班药业有限公司 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用
CN104447564B (zh) * 2014-11-24 2016-08-31 广州天赐高新材料股份有限公司 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法
CN104402873A (zh) * 2014-12-02 2015-03-11 千辉药业（安徽）有限责任公司 一种奥美沙坦酯中间体的制备方法
CN105481842A (zh) * 2015-12-15 2016-04-13 江苏中邦制药有限公司 一种奥美沙坦酯的制备方法
EP3434284A4 (en) 2016-03-24 2019-11-13 Daiichi Sankyo Company, Limited MEDICINE FOR THE TREATMENT OF KIDNEY DISEASE
CN106749195A (zh) * 2016-12-30 2017-05-31 青岛黄海制药有限责任公司 一种奥美沙坦酯中间体杂质合成、鉴定的方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN109081812B (zh) * 2018-08-30 2022-08-16 黄冈鲁班药业股份有限公司 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物
KR102131359B1 (ko) 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
CN112778209B (zh) * 2019-11-04 2024-05-14 宜昌东阳光长江药业股份有限公司 一种二酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4916129A (en) 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
CA2016710A1 (en) 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
WO1991012002A1 (en) * 1990-02-13 1991-08-22 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Also Published As

Publication number Publication date
IL101034A (en) 1996-10-16
CN1065063A (zh) 1992-10-07
ES2156866T3 (es) 2001-08-01
DK0545912T3 (da) 2001-06-18
CN1101384C (zh) 2003-02-12
CN1189490A (zh) 1998-08-05
LU91571I2 (fr) 2009-07-13
EP0503785B1 (en) 2001-04-25
DE69231801D1 (de) 2001-05-31
CA2229000C (en) 2002-04-09
HU223667B1 (hu) 2004-11-29
DK0503785T3 (da) 2001-06-18
CA2229000A1 (en) 1992-08-22
IL114996A (en) 1997-07-13
HU9601179D0 (en) 1996-07-29
ES2157895T7 (es) 2012-06-14
FI112942B3 (fi) 2012-03-13
NO920688D0 (no) 1992-02-21
NO304516B3 (no) 2012-06-11
KR920016429A (ko) 1992-09-24
IE970752A1 (en) 2000-02-23
NO2003009I2 (en) 2007-12-11
CN1045770C (zh) 1999-10-20
NZ241681A (en) 1993-07-27
CN1121859C (zh) 2003-09-24
AU1112592A (en) 1992-08-27
NO2006012I1 (no) 2006-10-30
AU647887B2 (en) 1994-03-31
FI920749A0 (fi) 1992-02-20
HU223338B1 (hu) 2004-06-28
NO304517B1 (no) 1999-01-04
IL114996A0 (en) 1995-12-08
ES2157895T3 (es) 2001-09-01
NO954507D0 (no) 1995-11-09
CN1188645A (zh) 1998-07-29
GR3035906T3 (en) 2001-08-31
JPH07121918B2 (ja) 1995-12-25
HU9200578D0 (en) 1992-05-28
NL300133I1 (nl) 2003-10-01
PT503785E (pt) 2001-08-30
CA2061607A1 (en) 1992-08-22
IE920540A1 (en) 1992-08-26
EP0545912A2 (en) 1993-06-09
DE122011000011I1 (de) 2011-06-16
GR3035909T3 (en) 2001-08-31
DE69231798T3 (de) 2012-07-12
DE10299043I1 (de) 2003-03-27
NO2011013I1 (no) 2011-08-22
CZ51692A3 (en) 1993-03-17
IS3819A (is) 1992-08-22
NO920688L (no) 1992-08-24
ATE200778T1 (de) 2001-05-15
NO304516B1 (no) 1999-01-04
LU91056I2 (fr) 2004-10-19
DE69231801T2 (de) 2001-12-06
IS1756B (is) 2000-12-28
FI955248A0 (fi) 1995-11-02
NO2009019I1 (no) 2009-09-21
FI955248A (fi) 1995-11-02
FI112942B (fi) 2004-02-13
DE10299043I2 (de) 2003-08-07
DE69231798D1 (de) 2001-05-31
CZ289194B6 (cs) 2001-11-14
HU211934A9 (en) 1996-01-29
JPH0578328A (ja) 1993-03-30
HUT60475A (en) 1992-09-28
NO954507L (no) 1992-08-24
DE122009000024I1 (de) 2009-09-17
CA2061607C (en) 1999-01-19
EP0545912B1 (en) 2001-04-25
IL101034A0 (en) 1992-11-15
FI112941B (fi) 2004-02-13
LU91330I2 (fr) 2007-06-04
EP0503785A1 (en) 1992-09-16
RU2128173C1 (ru) 1999-03-27
EP0545912A3 (en) 1993-06-16
DE69231798T2 (de) 2001-12-06
DE122005000051I1 (de) 2006-01-26
NL300375I1 (nl) 2009-04-01
PT545912E (pt) 2001-08-30
FI920749A (fi) 1992-08-22
NL300133I2 (nl) 2004-03-01
HK1011969A1 (en) 1999-07-23
KR0128289B1 (ko) 1998-04-02
HK1011361A1 (en) 1999-07-09
LU91847I2 (fr) 2011-09-26
ATE200777T1 (de) 2001-05-15
EP0503785B3 (en) 2012-02-29
NL300227I1 (nl) 2006-06-01

Similar Documents

Publication Publication Date Title
RU95101430A (ru) Производные 1-бифенилметилимидазола, их получение, фармацевтическая композиция, способ лечения или профилактики гипертонии
PT86188A (en) Process for the preparation of rebeccamycin analogs and of pharmaceutical compositions containing the same
BR8201589A (pt) Composto,composicao farmaceutica,processo para tratar e/ou evitar a hipertensao,insuficiencia cardiaca congestiva,arritmia,enxaqueca pertubacoes vasospasticas e asma num mamifero e processo para a preparacao de tal composto
ES8503667A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina.
AU1507888A (en) New bicyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
RU94046387A (ru) Производные пиримидина, способ их получения, фармацевтическая композиция, ее применение и промежуточные продукты
AU2533492A (en) New nitrogen-containing bicyclic compounds, process for preparing them and pharmaceutical compositions containing them
ES8205770A1 (es) Procedimiento para la preparacion de derivados de 2,3-indo- lediona
RU95104235A (ru) Агент для контроля плодовитости и содержащая его фармацевтическая композиция
ES8304971A1 (es) Un procedimiento para la preparacion de derivados de tiocarbapenem 3-sustituidos.
AU586477B2 (en) Hexenoic acids
AU4953997A (en) New histidine derivatives, preparation process, and their use as free antiradical agents
ES8504182A1 (es) Procedimiento para preparar nuevos derivados de piperidina
DE3471654D1 (en) Ûbis(hydroxymethyl)-methyl¨-isoquinoline derivatives, process for preparing them and pharmaceutical compositions containing them
GB1380145A (en) Acetamidine derivatives process for preparing the same and pharma ceutical uses thereof
ES557436A0 (es) Un procedimiento para preparar nuevos derivados de imidazol
ES466867A1 (es) Procedimiento para la obtencion de 2,4-diclorofenil-imidazo-lil-etanonas y etanoles.
GB1412663A (en) 2- 4-biphenylyl- tetrahydrofurans and pharmaceutical compositions containing them
AU7384381A (en) Substituted oxadiazoles
DE69528984T2 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
ES8600760A1 (es) Procedimiento para preparar 2-((3, 4-metilendioxi)-fenetil)-5-((3-carboxamido-4-hidroxi)- -hidroxibencil)-pirrolidina
GEP19981168B (en) Benzimidazole derivatives and pharmaceutically acceptable salts thereof, intermediate compounds, method of their reception, stable crystals, a composition for inhibition of angiotensin ii
GB1427849A (en) Substituted 3-chloro-2-hydrazonomethyl-4-aza-2,4-pentadiene nitriles, a method for producing them and medicaments containing them

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner